Please try another search
Alzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer’s disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study. The company was incorporated in 2011 and is based in Mölndal, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Anders Sandberg | 52 | 2011 | Chief Scientific Officer |
Carol Routledge | - | 2018 | Director |
Clas Malmestrom | 59 | 2015 | Director |
Anders Waas | 67 | 2018 | Director |
Lena Degling Wikingsson | 61 | 2020 | Independent Director |
Per-Goran Gillberg | - | 2020 | Independent Director |
Anders Blom | 55 | 2021 | Director |
Jesper Dahlberg | - | - | Deputy Board Member |
Julian Aleksov | 59 | 2023 | Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review